Sivik Global Healthcare LLC Takes $3.70 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Sivik Global Healthcare LLC acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 50,000 shares of the medical research company’s stock, valued at approximately $3,702,000. Edwards Lifesciences accounts for about 1.9% of Sivik Global Healthcare LLC’s holdings, making the stock its 24th largest position.

Other hedge funds have also added to or reduced their stakes in the company. Bowman & Co S.C. lifted its stake in shares of Edwards Lifesciences by 1.2% during the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after buying an additional 148 shares in the last quarter. Mount Yale Investment Advisors LLC lifted its position in shares of Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after acquiring an additional 162 shares in the last quarter. JFS Wealth Advisors LLC boosted its stake in shares of Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after acquiring an additional 166 shares during the period. Seascape Capital Management grew its position in shares of Edwards Lifesciences by 0.5% during the third quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after purchasing an additional 174 shares in the last quarter. Finally, Cooper Financial Group raised its stake in Edwards Lifesciences by 2.8% during the 4th quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock valued at $479,000 after purchasing an additional 175 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

Shares of EW opened at $73.49 on Thursday. The firm has a market cap of $43.34 billion, a PE ratio of 10.50, a price-to-earnings-growth ratio of 3.54 and a beta of 1.11. The company’s 50 day simple moving average is $72.37 and its 200-day simple moving average is $70.06. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Analyst Upgrades and Downgrades

Several analysts have commented on EW shares. Wolfe Research cut shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target on the stock. in a research note on Thursday, January 16th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Truist Financial restated a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the company from $82.00 to $90.00 in a report on Monday, December 16th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 11th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $79.19.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,717,841.12. The trade was a 9.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,000 shares of company stock worth $2,195,180. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.